WNX Stock Chart & Stats
6.00 p
--
Market closed
6.00 p
--
Day’s Range― - ―
52-Week Range3.00 p - 15.60 p
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.95K
Market Cap
£2.28M
Enterprise Value12.64M
Total Cash (Recent Filing)£975.00K
Total Debt (Recent Filing)£10.03M
Price to Earnings (P/E)―
Beta-0.17
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding73,026,810
10 Day Avg. Volume5,525
30 Day Avg. Volume1,951
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.69
Price to Sales (P/S)0.33
P/FCF Ratio-11.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.6
Revenue Forecast (FY)£2.53B
Bulls Say, Bears Say
Bulls Say
Balance-sheet StabilityA moderate debt-to-equity ratio (~0.48) and a healthy equity ratio provide the company with financial flexibility and lower immediate refinancing risk. This balance-sheet stability supports operations and modest investment in marketing or product rollouts over the coming months without urgent recapitalisation.
Positive Gross Margins With Modest Revenue GrowthModest revenue growth coupled with positive gross margins indicates the business can cover direct product costs and sustain unit economics. If operating expenses are controlled, this mix supports operating leverage potential and a durable path to margin improvement across several quarters.
Integrated Consumer-health Business ModelAn end-to-end model—brand development, formulation and multi-channel distribution (wholesale and direct-to-consumer)—creates structural go-to-market capabilities. Owning formulation and retailer relationships helps capture margins and scale new products more predictably over time.
Bears Say
Weak Cash GenerationPersistent negative operating and free cash flows constrain working capital and limit the ability to fund inventory, marketing and growth internally. Over a multi-month horizon this raises reliance on external financing, increasing execution risk and potential dilution if new capital is required.
Ongoing Profitability PressureNegative net profit and EBIT margins indicate the core business is not yet converting sales into operating profits. Continued unprofitability erodes reserves and hampers reinvestment, making sustainable earnings recovery dependent on material cost control or meaningful revenue mix improvement.
Negative Return On EquityA negative ROE signals the company is destroying shareholder value on its existing capital base, reducing internal funding capacity and investor confidence. Without a clear path to positive returns, management may need restructuring or external capital to restore long-term viability.
Wellnex Life Ltd News
WNX FAQ
What was Wellnex Life Ltd’s price range in the past 12 months?
Wellnex Life Ltd lowest share price was 3.00 p and its highest was 15.60 p in the past 12 months.
What is Wellnex Life Ltd’s market cap?
Wellnex Life Ltd’s market cap is £2.28M.
When is Wellnex Life Ltd’s upcoming earnings report date?
Wellnex Life Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 41 days.
How were Wellnex Life Ltd’s earnings last quarter?
Wellnex Life Ltd released its earnings results on Feb 26, 2026. The company reported -0.014 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.014 p.
Is Wellnex Life Ltd overvalued?
According to Wall Street analysts Wellnex Life Ltd’s price is currently Overvalued.
Does Wellnex Life Ltd pay dividends?
Wellnex Life Ltd does not currently pay dividends.
What is Wellnex Life Ltd’s EPS estimate?
Wellnex Life Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wellnex Life Ltd have?
Wellnex Life Ltd has 73,026,810 shares outstanding.
What happened to Wellnex Life Ltd’s price movement after its last earnings report?
Wellnex Life Ltd reported an EPS of -0.014 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Wellnex Life Ltd?
Currently, no hedge funds are holding shares in GB:WNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wellnex Life Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.69%
12-Months-Change
Fundamentals
Return on Equity
-92.72%
Trailing 12-Months
Asset Growth
-17.21%
Trailing 12-Months
Company Description
Wellnex Life Ltd
Wellnex Life Limited, together with its subsidiaries, develops, markets, and sells health and wellness products in Australia, New Zealand, and the United Kingdom. The company offers topical anti-inflammatory creams, sprays, and roll-ons under the Pain Away brand; caffeine energy liquid capsules and multivitamins under the Wakey Wakey brand; sleep aid products under the Nighty Night brand; teeth whitening solutions under the Mr. Bright brand; pain relief capsules under the Wagner Liquigesics brand; medicinal cannabis under the Wellness Life brand; and over-the-counter medicines under the Pharmacy Own brand. It is also involved in the holding of intellectual properties and trademarks of its products; brand and pharma solution businesses; and investment activities. The company was formerly known as Wattle Health Australia Limited and changed its name to Wellnex Life Limited in June 2021. Wellnex Life Limited was incorporated in 2011 and is headquartered in Port Melbourne, Australia.
Technical Analysis
―
Bubs Australia Ltd.
―
Nuchev Pty Ltd
―
Holista Colltech Limited
―
Nutritional Growth Solutions Ltd.
―